The gene therapy field remains on edge, but recent developments—including leadership changes at the FDA—offered a glimmer of hope at a high-profile conference in Rome last week.
Tim Hunt, CEO of the Alliance for Regenerative Medicine (ARM), pointed to two key reasons for cautious optimism during his remarks at the event. First, he cited the recent approvals of rare disease treatments by companies such as Rocket Pharmaceuticals and Regeneron Pharmaceuticals. Second, he highlighted the announcement that Vinay Prasad, the FDA’s top regulator overseeing gene therapies, cell therapies, and vaccines, would be leaving the agency.
Prasad’s departure, announced last week, was a recurring theme at the conference, underscoring how closely the gene therapy sector in Europe is watching regulatory shifts in the United States. The FDA’s decisions, even from 4,500 miles away, continue to shape the industry’s trajectory.
The conference, designed to address both the opportunities and challenges facing the gene therapy sector in Europe, ultimately couldn’t escape the influence of U.S. regulatory actions. Hunt’s remarks reflected the sector’s sensitivity to leadership changes at the FDA, which have historically had ripple effects across the global industry.
Related articles
Kratom Use Surges in the US: Rising Addiction and Mental Health Concerns
A national study of kratom use in the US found rising popularity among young adults, and it is linked to addiction and mental health issues, according...
STAT+ Roundup: New Hires and Promotions in Biotech and Pharma
Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others....
U.S. Pressures Germany on Drug Prices Amid FDA Restructuring Concerns
And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about we...
Mail-Order Abortion Pills Remain Legal Amid Legal Uncertainty
In a discussion about the best fruits, my STAT colleague Alexa Lee and I agreed that peaches have been mid in recent years. Is this just a New York Ci...
FDA Rejects Melanoma Drug RP1 Amid Leadership Controversy Under Makary
The FDA’s recent decision to withhold approval of a new skin cancer treatment fell like a hammer on doctors who treat melanoma and patients who saw th...
Why Changing Pill Colors and Shapes at 73 Are More Than Just an Annoyance
At the ripe old age of 73, I take six drugs — four prescription and two over-the-counter pills — every day. I keep careful track of them. But recently...
Supreme Court Blocks Restrictions on Abortion Pill Mifepristone, Ensuring Continued Access
WASHINGTON — The Supreme Court on Thursday preserved women’s access to a drug used in the most common method of abortion, rejecting lower-court restri...
Dr. Makary's Exit and the Future of Cassidy's Senate Seat: Key Health Policy Shifts
This week’s episode of “The Readout LOUD” is all about health politics. We bring on FDA reporter Lizzy Lawrence to discuss Makary’s departure — why he...